An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
This article is part of a themed section on Recent Progress in the Understanding of Relaxin Family Peptides and their Receptors. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.10/issuetoc.
Agoulnik AI, Agoulnik IU, Hu X, Marugan J (2017). Synthetic non‐peptide low molecular weight agonists of the relaxin receptor 1. Br J Pharmacol 174: 977–989.
-
PMC
-
PubMed
Alexander SPH, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015a). The Concise Guide to PHARMACOLOGY 2015/16: G protein‐coupled receptors. Br J Pharmacol 172: 5744–5869.
-
PMC
-
PubMed
Alexander SPH, Fabbro D, Kelly E, Marrion N, Peters JA, Benson HE et al. (2015b). The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol 172: 6024–6109.
-
PMC
-
PubMed
Ang SY, Hutchinson DS, Patil N, Evans BA, Bathgate RAD, Halls ML et al (2017). Signal transduction pathways activated by insulin‐like peptide 5 at the relaxin family peptide RXFP4 receptor. Br J Pharmacol 174: 1077–1089.
-
PMC
-
PubMed
Calvez J, de Ávila C, Timofeeva E (2017). Sex‐specific effects of relaxin‐3 on food intake and body weight gain. Br J Pharmacol 174: 1049–1060.
-
PMC
-
PubMed